Nexalin announces pivotal HALO Clarity trial for insomnia to support FDA de novo submission

Nexalin Technology, Inc.

150-patient, triple-blinded, sham-controlled randomized study via decentralized NeuroCare virtual clinic with Lindus Health.
Designed to support planned FDA de novo submission for moderate to severe insomnia treatment.
Builds on prior published 120-patient study showing significant sleep improvements with no adverse effects.
Targets $multi-billion insomnia market; ~30M U.S. adults seek drug-free options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.